We advised ADC Therapeutics on the transaction involving its common shares and pre-funded warrants

Davis Polk advised ADC Therapeutics SA in connection with a private placement of 12,911,347 of its common shares at a price of $1.42 per share and, in lieu of common shares, pre-funded warrants to purchase up to 48,088,653 common shares at a price of $1.324 per pre-funded warrant. The gross proceeds of the offering assume cash exercise of the pre-funded warrants. ADC Therapeutics is listed on the NYSE under the ticker symbol “ADCT.”

ADC Therapeutics is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs). The company is advancing its proprietary ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. ADC Therapeutics is based in Lausanne (Biopôle), Switzerland.

The Davis Polk capital markets team included partner Yasin Keshvargar and associates Marcus Holtzman and Rose Cheng. All members of the Davis Polk team are based in the New York office.

Copy link to share post